Alenta 10mg Getz medicine for osteoporosis (1 blister x 10 tablets)
Dosage form Box of 1 blister x 10 tablets
Specifications Alendronic Acid
Ingredient Osteoporosis, osteoporosis in South, Paget bone
Ingredient
| Composition information | Content |
| Alendronic Acid | 10mg |
Uses
indications
Alenta 10 mg drug is indicated in the following cases:
At the cell level, Alendronat shows the local effects on the absorption position of the bone, especially right below the cell cancellation. The cancellation of the cells attached to the surface of the bone but often lacks rugged folds, which indicates the activity of the cell cancellation.
Alendronat does not interfere with the attraction or adhesion of the cell cancellation, but it inhibits the activity of the cell cancellation. When entering the bone block, Alendronat does not have pharmacological effects. Therefore, Alendronat must be used continuously to inhibit the cancellation of the cells at the newly formed surfaces.
Pharmacokinetics
absorption
Like bisphosphonate drugs, Alendronat is absorbed in a small amount after drinking. Absorbent absorption by food, especially foods containing calcium or other valence ions. Born is about 0.4% when taking the medication half an hour before eating, decreasing from 0.7% during fast meals, not significant absorption when taking the drug 2 hours after meals.
Distribution
The volume of distribution is in a stable state, including bone, at least 28 l in humans. The concentration of drugs in plasma when used by oral equal is too low (lower than 5 ng/ml). The drug combines about 78% of plasma protein.
Metabolism
There is no evidence that alendronat is metabolized in animals or humans.
Elimination
About half of the absorption is excreted through urine. The rest is accumulated in the bone. In humans, the sale time of the drug is estimated to be over 10 years, perhaps reflecting the release of alendronat from the bone.
Before taking Alenta 10mg Getz medicine for osteoporosis (1 blister x 10 tablets)
How to use
Alenta 10 mg is used by oral.
To absorb the satisfactory alendronat, Alendronic acid must be taken when hungry when waking up in the morning, only with filtered water, at least 30 minutes before eating, drinking or other drugs during the day. Other drinks (including mineral water), food and some drugs are capable of reducing the absorption of alendronat. To support the distribution of drugs into the stomach and thus reduce the risk of irritation/unwanted effect on the spot and in the esophagus.
Should only drink Alenta when starting a new day with a glass of water (not less than 200 ml). Alenta tablets should be swallowed. The pill should not chew, suck or dissolve in the mouth because of the risk of mouth -to -mouth ulcer. Patients should not lie down until the first meal of the day, at least 30 minutes after taking the drug.
Do not drink alenta when going to bed or before waking up on the new day. Patients should be supplemented with calcium and vitamin D if the diet is incomplete.
Dosage
Optimized bisphosphonate treatment for osteoporosis has not been set. The demand for continued treatment should be re -evaluated periodically based on the benefits and potential risks of alendronic acid in each patient, especially after use for 5 years or more.
Treatment of postmenopausal osteoporosis
recommended dose is 10 mg once a day.
Osteoporosis treatment in men
recommended dose is 10 mg once a day.
Treatment and prevention of osteoporosis caused by glucocorticoid
For postmenopausal women who are not treated with estrogen, the recommended dose is a 10 mg tablet daily.
Dosage for Alenta 70 mg: The recommended dose is a 70 mg tablet per week. Patients should be instructed that if you forget a dose of 70 mg once a week, take a tablet in the morning after remembering. Patients should not use two capsules on the same day but should return to use one tablet once a week, as the original plan on the selected day.
Elderly
In clinical trials, there is no difference in age related to the effect of effectively or safety data of Alendronat. Therefore, there is no need to adjust the dose for older patients.
kidney failure
No dose adjustment in patients with glomerular filtration level (GFR) is greater than 35 ml/min. Alendronat is not recommended for patients with renal function if GFR is below 35 ml/min, because there is no experience in this.
Used for patients with liver failure
No dose adjustment.
Children
Alendronate sodium is not recommended for children under 18 years of age because there is not enough data on safety and effectiveness related to osteoporosis in children.
Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do
do when overdose? Overdose can cause hypocc calcium, lower hemorrhagic phosphate, existent adverse effects in the gastrointestinal tract such as digestive disorders, heartburn, esophagitis, inflammation or stomach ulcers. It is necessary to drink milk or antacids to combine with Alendronat. Due to the risk of esophageal irritation, do not cause vomiting and patients need to be completely vertical.
In an emergency, call the 115 emergency center immediately or go to the nearest local health station.
What to do when you forget a dose? However, if close to the next dose, skip the forgotten dose and take the next dose at the time as planned. Do not drink twice as prescribed.
Side Effects
When using Alenta 10 mg, you may experience unwanted effects (ADR).
The following unwanted effects are grouped by frequency: Very common (ADR> 1/10), common (1/100 Very common (ADR> 1/10) Common (1/100 Uncommon, 1/1000 Other disorders: Symptoms such as acute reactions (muscle pain, weakness and rare fever), when starting treatment. Rare (1/10000 Instructions on how to handle ADR When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
Contraindicated
Alenta 10 mg is contraindicated in the following cases:
Caution when using
Caution
It is necessary to consider the causes of osteoporosis other than the causes of estrogen deficiency, age and the use of glucocorticoids.
Must adjust the condition of hypocalcemia before starting treatment with sodium alendronat.
Other disorders that affect the metabolism of resistant (such as vitamin D deficiency) should also be treated. For these patients, serum calcium concentration should be monitored as well as symptoms of blood calcium.
Ensuring adequate calcium amounts and vitamin D is especially important for patients with bone paget and patients who are using glucocorticoids because of the mitigation of calcium and serum phosphate without accompanying symptoms that may occur when treated with sodium alendronat.
Precautions on gastrointestinal
The treatment doctor should be alert to the symptoms that can occur reactions on the esophagus including magnetic mixing disorders, they swallow pain, pain behind the breastbone, heartburn or worsening. These patients should stop using sodium alendronat.
Because sodium alendronat has the effect of irritation on the stomach -intestinal mucus and can worsen the gastrointestinal diseases, therefore, it is necessary to be cautious when using sodium alendronat for patients with progressive digestive tract disorders.
localized jaw bone necrosis
localized jaw bone necrosis (ONJ), often associated with tooth extraction and/or local infection (including bone inflammation) recorded in cancer patients being treated with mainly intravenous bisphosphonate. Some patients are also chemotherapy or use corticosteroids. The local jaw bone necrotic also records in patients with osteoporosis using oral bisphosphonate.
The following risk factors are considered when assessing the risk of each patient may develop local jaw necrotic necrosis:
Should consider dental examination to take appropriate preventive measures before starting treatment with oral bisphosphonate in patients with bad teeth.
During treatment, these patients should avoid invasive dental procedures if possible. For patients with local jaw necrotic development when using bisphosphonate, dental surgery will make the condition worse. For patients who need a dental procedure, there is no available data to propose to stop using bisphosphonate, reducing the risk of local jaw necrotic necrosis. Clinical assessment of a treating doctor should guide the control plan on each patient based on the risk and benefits assessment on each individual.
During the treatment process with bisphosphonat, all patients need to be encouraged to maintain good oral hygiene, regular dental examination and report any oral symptoms such as teeth movement, pain or swelling.
muscle, bone and joint pain
Muscle, bone and joint pain is also recorded in patients using bisphosphonate. According to the experience of using the drug after circulation, these symptoms are rarely serious or lose their ability to exercise. The start of these symptoms from 1 day to a few months after the beginning of treatment. Most patients will mitigate symptoms after stopping the drug. Some patients recur when reused with the same medicine or with another bisphosphonate.
Bades on the thigh bone are not typical
The tip of the thigh bone is not typical recorded when using bisphosphonate, most patients treat prolonged osteoporosis. Short and horizontal cross fractures can occur anywhere along the thigh bone just below the smaller partition to the above rotating bone. The fractures occur after a minor or non -existing injury and some patients who have thigh pain or groin, often combined with bone stretch marks, a few weeks to a few months before the thigh fracture completely appears.
Fractures usually occur on both sides; Therefore, the opposite femoral bone must be tested in patients treated with bisphosphonate that are suffering from the femur fracture. The healing of the wound in this break has also been reported. The stopping use of bisphosphonate in patients suspected of not typical femoral fractures should be considered to assess the benefits and risks in each patient. During treatment with bisphosphonate, patients should report any symptoms of thigh, hip or groin pain and any patient with such symptoms should be assessed as incomplete thigh fractures.
Skin reaction
The experience of using drugs after circulation shows that rare reports on serious skin reactions include Stevens - Johnson syndrome and epidermal necrosis due to poisoning.
Patients with renal failure
Do not use sodium alendronate for patients with severe renal failure (creatinine clearance rate below 35 ml/minute) due to not having much experience in using drugs for kidney failure.
Mineral metabolism
Other disorders that affect mineral metabolism (such as vitamin D deficiency and hypoglycemia) should also be effectively treated. For patients with these symptoms, calcium concentration in plasma and symptoms of blood calcium lower should be monitored during treatment with Alendronat 70 mg acid, due to the positive effects of alendronat in increasing bone -minerals density, reducing calcium and phosphate in the blood can also occur, especially patients using glucocorticoids to reduce calcium absorption.
This situation is usually small and disadvantaged. However, there are also rare reports on the lower blood calcium, which sometimes becomes serious and often occurs in patients with atopic (such as reducing parathyroid gland, deficiency of vitamin D and less calcium calcium). Make sure to provide adequate calcium and vitamin D is especially important in patients using glucocorticoids.
Glucocorticoid osteoporosis
The risk compared to the benefits of using sodium alendronat to treat patients using glucocorticoids below 7.5 mg of prednison or the equivalent has not been published. Before starting treatment, it is necessary to determine the level of hormones of both men and women and should consider an appropriate alternative therapy. The mineral density should be evaluated before using sodium alendronat with glucocorticoid and repeated 6-12 months later.
Children
Safety and effectiveness of sodium alendronat on children has not been published.
excipients
Alenta contains lactose. Patients with rare genetic problems galactose intolerance, Lapp Lactase or Glucose - Galactose should not use this drug.
The ability to drive and operate machinery
There are no studies conducted on the effects of the drug on driving and operating machinery. However, unwanted effects when using Alendronat 70 mg acid can affect the ability to drive and operate machinery in some patients. Meeting Alendronat 70 mg of each individual may change.
Pregnancy
There is no research in pregnant women. Sodium Alendronat should only be used during pregnancy if the benefits are higher than the risk of mother and fetus.
The period of breastfeeding
It is not known whether sodium alendronat is excreted in breast milk or not. Because a lot of drugs can be excreted in breast milk, so it is necessary to use sodium alendronat for women who are breastfeeding.
Drug interaction
estrogen/Factory replacement therapy
Combining the use of sodium alendronate and hormones replacement therapy will increase bone mass, while reducing the rate of bone metabolism more than using these drugs separately. Safety and tolerance of drug combination similar to individual use.
Additional calcium/antacids
antacids and calcium supplements as well as some other oral drugs can hinder the absorption of sodium alendronate. Therefore, the patient must wait at least half an hour after taking sodium alendronat to use any other drug.
aspirin
The level of side effects on the gastrointestinal tract increases in patients using sodium alendronate combination at a dose greater than 10 mg/day with products containing aspirin.
Non -steroid anti -inflammatory drugs (NSAID)
Because nonsteroidal anti -inflammatory drugs are related to stomach -intestinal irritation, it is necessary to be cautious when coordinated with sodium alendronat.
Storage
Store in a dry place, avoid light and humidity, temperatures below 30 ° C.
This drug is only used by prescription. To be out of reach of children.
Expiry date: 36 months from the date of manufacture. Do not use overdue drugs stated on the packaging.
Other drugs
- AVOCA CAUSTIC PENCIL 95% W/W CUTANEOUS STICK
- Ecalta
- MICROGYNON 30 TABLETS
- NovoRapid
- THADEN CAPSULES 25MG
- TETRALYSAL 300MG HARD CAPSULES
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions